Myovant to Submit Lead Drug For Prostate Cancer Approva...
(BioPharma Dive) Nov 19, 2019 - Myovant Sciences said Tuesday a late-stage trial studying its lead drug in advanced prostate cancer met its pr...
Morphosys to Boost Size Of Tafasitamab Drug Trial On En...
(Reuters) Nov 18, 2019 - German biotech company Morphosys said more patients would be recruited for a study testing its most advanced drug aga...
Ahmed Kaseb, MD, elaborates on the phase 1b study investigating atezolizumab + bevacizumab in HCC
Arndt Vogel, MD, offers his opinion on pemigatinib in the management of cholangiocarcinoma
November 2019 Edition
Patient-reported outcomes (PROs) monitoring has been shown to have multiple benefits for cancer patients, while also representing an important tool for providers in implementing value-bas...
November 2019 Edition
Artificial intelligence (AI) has the potential to identify patients with cancer at high risk of unplanned utilization of acute care, a critical healthcare cost driver. OBR spoke with Card...
Third-Line Treatment in Metastatic Colorectal Cancer Po...Oct 07, 2019
Targeted oral tyrosine kinase inhibitors (TKIs) have an established role in third-line treatment of metastatic colorectal cancer (mCRC), but an expert outlined an...
ESMO Opens with Survival Benefits from Long-Term Data i...Sep 30, 2019
The 2019 European Society of Medical Oncology (ESMO) opened with a series of trials with positive overall survival (OS) data. Generally considered the gold standa...
Rapid Integration of Information Presented at 2019 ASCO...Jul 15, 2019
OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in ...
Stemming from the user preference that you set, stay informed and increase your productivity via 27/7 web based access to Ontellitrac and a customized email alert system summarizing the most recent oncology-specific information available.Learn More
The Oncology Business Dynamics Learning Platform addresses the need to have a high level of understanding of the non-clinical issues that are influencing the decision making process for hem/oncs today.Learn More
San Antonio, TX
New Orleans, LA
San Diego, CA
|Date||Company and Product|
Celgene / bluebird bio,
Karyopharm Therapeutics ,